Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FX-111 in Metastatic Castration-Resistant Prostate Cancer
NCT07719361Phase 1Recruiting
- Sponsor
- Flare Therapeutics
- Start
- Jul 2026
- Primary completion
- Feb 2028
- Countries
- 1
01
Overview
Phase 1, open-label trial of FX-111 in metastatic castration-resistant prostate cancer (mCRPC) (5 arms), sponsored by Flare Therapeutics. Primary endpoint: Adverse Events at 6 months. Started Jul 2026; status: recruiting.
02
Drugs
FX-111
03
Conditions
metastatic castration-resistant prostate cancer (mCRPC)
Beyond the preview
Go deeper on NCT07719361.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07719361.